Market Overview

Jazz Pharma Begins Trial of IV Administered Erwinaze

Related JAZZ
Benzinga's Top Downgrades
Earnings Scheduled For November 9, 2015
Don't Forget Hot Sectors When Looking For New Stocks (Investor's Business Daily)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Posted-In: News FDA


Related Articles (JAZZ)

View Comments and Join the Discussion!

Get Benzinga's Newsletters